Presenter: Samuel S. Chuang, PhD., the Director of Scientific Advisory Services for Charles River Labs. With over 20 years of academic, biotechnology and nonclinical CRO experience, Sam provides scientific and regulatory guidance in developing research strategies at all stages of drug candidate development from early discovery and target validation up to pre-approval. He has experience across a wide range of drug modalities including small and large molecules, nucleotides, and advanced therapies. He is responsible for managing seasoned non-clinical safety assessment experts engaged in providing scientific advice on drug development strategies. Sam has a PhD in microbiology and immunology from the University of Tennessee, Health Science Center, and a bachelor’s degree in biology from The University of Western Ontario. He is also a member of the American Society of Toxicology. Sam’s specialty: working with and advising startups.
Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts. Its team of 22,000 dedicated employees are focused on providing clients with exactly what they need to improve and expedite the discovery, early-stage development and safe manufacture of new therapies for the patients who need them.
With decades of industry experience and proven abilities to navigate the complex and changing regulatory landscape, the SAS team can design and manage lean and robust preclinical programs. The team provides flexible, responsive, and personalized support, and each client’s project is managed with the same dedication and attention as if it were our own. With access to the industry’s most comprehensive portfolio – from early discovery to market support – its team will map your journey through drug development.